Summary

The global Advanced Therapy Medicinal Products CDMO Market is expected to grow at a significant rate of around 14% during the forecast period. Advanced Therapy Medicinal Products (ATMPs) are a new category of medicines that offer innovative treatments for various diseases and medical conditions. They include cell and gene therapies, tissue-engineered products, and other innovative treatments. The Contract Development and Manufacturing Organizations (CDMO) market for ATMPs provides services for the development and manufacturing of ATMPs, helping companies bring their products to market more quickly and cost-effectively.

The market for ATMPs is growing rapidly, driven by the increasing demand for new and effective treatments for various diseases and conditions, including cancer, genetic disorders, and chronic diseases such as diabetes and heart disease. The market is further driven by advancements in biotechnology and the increasing availability of cutting-edge technologies and the increasing demand for new and effective treatments for rare genetic diseases and conditions, the market is expected to continue growing in the coming years. For instance, as per the United States Center for Disease Control and Prevention article on spinal muscular atrophy (SMA) updated in December 2021, SMA is a genetic disorder that affects around 1 in every 10,000 people. Therefore, it is one of the most common rare diseases.

CELONIC Group; FUJIFILM Corporation; Bio Elpida; Rentschler Biopharma SE; AGC Biologics; Catalent, Inc; Lonza; WuXi AppTec Co., Ltd.; BlueReg; Thermo Fisher Scientific Inc. are some of the key players in the market. Several M&As along with partnerships have been undertaken by these players to facilitate customers with hi-tech and innovative products/technologies.

Insights Presented in the Report
“Amongst product, cell therapy category to witness fastest growth rate during the forecast period”
Based on product, the market is segmented into gene therapy, cell therapy, tissue engineered, and others. Amongst, cell therapy category to witness fastest growth rate during the forecast period. This segment includes the production and manufacturing of cellular products, such as stem cells, T-cells, and other cell-based treatments, which are used to treat a range of diseases and conditions, including cancer, genetic disorders, and degenerative diseases. Companies in this segment offer a range of services, including cell processing, cell banking, and cell therapy product development and commercialization. These factors are expected to contribute to the growth of this segment.

“Amongst indication, the cardiology category held a significant share in the market in 2021.”
On the basis of indication, the market is categorized into oncology, cardiology, central nervous system, musculoskeletal, infectious disease, and others. Among these, the cardiology category held a significant share in the market in 2021. This is mainly due to the several factors, including increasing prevalence of cardiovascular diseases such as heart attack, stroke, and heart failure, are leading cause of death and disability worldwide. The increasing prevalence of these diseases is driving the demand for new and innovative treatments, including ATMPs.

“APAC to hold a significant share in the market”
For a better understanding of the market adoption of the advanced therapy medicinal products CDMO industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. The ATMPs CDMO market in the APAC region is expected to continue growing in the coming years, driven by factors such as increasing demand for ATMPs, rising investment in the healthcare industry, and growing awareness about the benefits of these therapies.

The other factors driving the growth of this market in the region include the presence of several ATMP CDMOs in the APAC region such as large multinational corporations and local companies. The ATMP CDMO market in the region is characterized by high competition, with companies constantly looking to improve their production processes and capabilities to stay ahead of their competitors.

Reasons to buy this report:
• The study includes market sizing and forecasting analysis validated by authenticated key industry experts.
• The report presents a quick review of overall industry performance at one glance.
• The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolio, expansion strategies, and recent developments.
• Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry.
• The study comprehensively covers the market across different segments.
• Deep dive regional level analysis of the industry.

Customization Options:
The global advanced therapy medicinal products CDMO market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.

ページTOPに戻る

Table of Contents